Financial Comparison of Amphastar Pharmaceuticals and ImmuCell Corporation

A comparison of Amphastar Pharmaceuticals and ImmuCell Corporation identified both companies as small-cap healthcare firms. The analysis noted that Amphastar Pharmaceuticals has higher gross revenue and earnings than ImmuCell Corporation. Furthermore, Amphastar Pharmaceuticals is trading at a lower price-to-earnings ratio than ImmuCell Corporation.

The report detailed differences in ownership structures, showing that 65.1% of Amphastar Pharmaceuticals shares are held by institutional investors, compared to 13.5% for ImmuCell Corporation. Amphastar Pharmaceuticals also has a higher percentage of shares held by company insiders, at 29.6%, versus 5.7% for ImmuCell Corporation.